Latest / The Well-Built Life / New Antiviral Breakthrough: POM-L-BHDU in Shingles & Herpes Treatment
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. So, let's dive into the intriguing
- 0:26Speaker 1: story of Pom LBH Dew. This drug has been making
- 0:30Speaker 1: waves in the scientific community, promising a new way to
- 0:33Speaker 1: combat shingles, chickenpox, and herpes infections. Tell me, Thomas, where
- 0:40Speaker 1: did this all begin?
- 0:41Speaker 2: Right, Rachel. It all kicked off in 2020 when Professor
- 0:44Speaker 2: David Chu and researcher Uma Singh started their work at
- 0:47Speaker 2: the University of Georgia. They were looking for a compound
- 0:51Speaker 2: that could target those pesky herpes viruses. Fast forward to
- 0:55Speaker 2: the 1st of October, 2025. And we see their research
- 0:59Speaker 2: hit the Journal of Medicinal Chemistry. That's a major milestone,
- 1:03Speaker 2: isn't it?
- 1:04Speaker 1: Absolutely. I mean, the journey from idea to published research
- 1:08Speaker 1: is no small feat. But this isn't just a case
- 1:11Speaker 1: of publish and quit. They took the publication as a
- 1:15Speaker 1: call to action, right? What have we learned about the
- 1:18Speaker 1: drug itself?
- 1:19Speaker 2: Precisely. POM-LBDU is designed to stop the virus from multiplying,
- 1:24Speaker 2: essentially breaking the replication cycle. The flexibility in its administration oral, EV,
- 1:29Speaker 2: topical means it could be a versatile treatment. It's like
- 1:32Speaker 2: having a Swiss Army knife for antiviral drugs, which is
- 1:36Speaker 2: quite exciting.
- 1:37Speaker 1: Exactly. The Swiss Army knife analogy works well. But let's
- 1:41Speaker 1: break down the timeline. We are talking about six years
- 1:45Speaker 1: of preclinical and laboratory testing before the publication. Can you
- 1:49Speaker 1: walk us through the key findings from those studies?
- 1:52Speaker 2: Sure. In vivo studies in mice showed that the topical
- 1:55Speaker 2: formulation effectively prevented viral spread beyond the treated area, which
- 2:00Speaker 2: is a big win, and the human skin laboratory studies
- 2:03Speaker 2: further backed up these findings, giving us some confidence. Yet,
- 2:08Speaker 2: as they say, the proof of the pudding is in
- 2:10Speaker 2: the eating, right?
- 2:12Speaker 1: Definitely. Transitioning from preclinical to clinical trials is a fraught period.
- 2:17Speaker 1: What do you think are the critical debates around POM-LBH2?
- 2:21Speaker 2: Well … Therese, the age-old question of efficacy versus safety.
- 2:25Speaker 2: Preliminary results are great in mice, but they don't always
- 2:28Speaker 2: translate to humans. Plus, interpreting the preclinical data and applying
- 2:33Speaker 2: it to human subjects isn't straightforward. There are differences in biology,
- 2:38Speaker 2: after all.
- 2:38Speaker 1: That's a tough nut to crack. And then Therese, the
- 2:41Speaker 1: choice of delivery method. The topical formulation seems promising for
- 2:45Speaker 1: skin infections, but what about systemic delivery for more widespread infections?
- 2:51Speaker 2: Absolutely. It's a balancing act. Topical might be more convenient,
- 2:56Speaker 2: but systemic delivery could be more effective in certain scenarios.
- 3:00Speaker 2: The research will have to determine where this drug excels
- 3:03Speaker 2: and where it falls short.
- 3:04Speaker 1: Speaking of research, let's touch on the stakeholders. University of Georgia,
- 3:09Speaker 1: the Research Foundation, and Enterogen Co. are all involved. What's
- 3:14Speaker 1: Enterogen's role?
- 3:15Speaker 2: Enterogen Co. acquired the patent rights, setting the stage for commercialization.
- 3:20Speaker 2: They are the main player here, tasked with seeing this
- 3:24Speaker 2: drug through to the finish line. It's not just about
- 3:27Speaker 2: discovery anymore. It's about making it useful for patients.
- 3:30Speaker 1: And let's not forget the non-profits like the Antikinser Foundation
- 3:34Speaker 1: and the Antiviral Therapeutics Association. They might play a supporting
- 3:39Speaker 1: role in the clinical trials.
- 3:41Speaker 2: Exactly. Their support could be crucial, providing resources and expertise
- 3:46Speaker 2: that might be essential for the drug's development. But, you know,
- 3:50Speaker 2: it's a long road ahead. There are still unsolved questions.
- 3:54Speaker 1: True. Like, will POM-LBH2 live up to its promise in
- 3:58Speaker 1: clinical trials? How will it fare in long-term use and
- 4:03Speaker 1: repeated dosing?
- 4:04Speaker 2: Those are valid points, Rachel. The path isn't clear, but
- 4:07Speaker 2: the potential is there. Positive outcomes could revolutionize treatment for
- 4:12Speaker 2: these infections, and even negative results could provide valuable insights
- 4:16Speaker 2: for refining the drug. It's an exciting time for antiviral therapeutics.
- 4:21Speaker 1: So, Thomas, let's dive into the nuts and bolts of
- 4:24Speaker 1: how POM-LBH2 actually works. Could you walk us through the
- 4:29Speaker 1: key mechanisms involved?
- 4:30Speaker 2: Absolutely. Rachel, at its core, POM-LBH2 is designed to inhibit
- 4:36Speaker 2: the virus replication cycle. Specifically, It targets enzymes that are
- 4:41Speaker 2: crucial for the virus to multiply and spread. Its multi-target
- 4:45Speaker 2: approach is really what sets it apart, as it can
- 4:47Speaker 2: effectively combat multiple herpesviruses, including the varicella, zoster virus and
- 4:53Speaker 2: herpes simplex viruses 1 and 2.
- 4:56Speaker 1: And how does it do this on a molecular level?
- 4:59Speaker 1: The science can be complex, but let's take it step
- 5:03Speaker 1: by step.
- 5:04Speaker 2: Sure. Imagine POMLB2 like a lock on a Dorich virus
- 5:08Speaker 2: has its own type of lock. POMLB2 can fit into
- 5:12Speaker 2: multiple locks, preventing the viruses from replicating. In the case
- 5:16Speaker 2: of the Varicella zoster virus, it specifically targets its DNA polymerase,
- 5:21Speaker 2: a key enzyme that viruses use to copy their genetic material.
- 5:25Speaker 2: Without this enzyme, the virus can't spread.
- 5:28Speaker 1: That's pretty clever. And the topical formulation is particularly interesting.
- 5:33Speaker 1: Can you explain how that works?
- 5:35Speaker 2: Absolutely. The topical approach is designed to target skin conditions
- 5:39Speaker 2: like shingles and cold sores. It's essentially delivering the drug
- 5:43Speaker 2: right at the site of infection, which can be more
- 5:46Speaker 2: effective and have fewer side effects than systemic treatment. In
- 5:50Speaker 2: lab studies, it's shown to effectively prevent viral spread, essentially
- 5:54Speaker 2: creating a localized barrier against the virus.
- 5:57Speaker 1: Fascinating. Now, could you tell us more about the stakeholder roles?
- 6:02Speaker 1: involved in this development process?
- 6:04Speaker 2: Of course. The University of Georgia, where the drug was developed,
- 6:08Speaker 2: has a critical role. They have done the bulk of
- 6:12Speaker 2: the initial research and are still involved in subsequent studies.
- 6:16Speaker 2: The University of Georgia Research Foundation licensed the technology to AntrogenCo,
- 6:22Speaker 2: a pharmaceutical company that's now driving the commercialization efforts. Antikinzer
- 6:27Speaker 2: Foundation and Antiviral Therapeutics Association are also key players, providing
- 6:33Speaker 2: support for trials and advocacy.
- 6:36Speaker 1: It's a well-rounded team. And what about the quantitative data?
- 6:40Speaker 1: We need to see some hard numbers to appreciate the
- 6:43Speaker 1: promise of POM-LBH-DU.
- 6:46Speaker 2: Well, there are some impressive preclinical and laboratory findings. In
- 6:51Speaker 2: in vivo studies with mice, POM-LB2 effectively prevented the spread
- 6:55Speaker 2: of the virus beyond the treated area. This is a
- 6:58Speaker 2: strong sign of its antiviral activity. Lab studies using human
- 7:02Speaker 2: skin samples showed similar results, adding weight to its potential
- 7:06Speaker 2: efficacy in human trials.
- 7:08Speaker 1: Those are encouraging results. But are there any critical debates
- 7:12Speaker 1: or contradictions that we should know about?
- 7:14Speaker 2: Yes, exactly. The transition from preclinical data to clinical trials
- 7:19Speaker 2: is always a big question mark. Preliminary results in animals
- 7:23Speaker 2: and cells don't always translate directly to human effectiveness. Also,
- 7:27Speaker 2: trias debate over how accurately preclinical models predict human outcomes,
- 7:32Speaker 2: especially considering the differences in biology and physiology between the two.
- 7:36Speaker 1: That's a good point. And on the flip side, there
- 7:39Speaker 1: are also alternative treatments available. How does POM-LBH2 stack up
- 7:44Speaker 1: against them?
- 7:45Speaker 2: Good question. It's important to consider the current landscape of
- 7:48Speaker 2: antiviral drugs. POM-LBH2 could potentially offer new, more versatile options,
- 7:54Speaker 2: particularly with its ability to combat multiple herpesviruses. But the
- 7:58Speaker 2: key will be in clinical trials, where its efficacy and
- 8:01Speaker 2: safety will truly be tested in humans. True.
- 8:05Speaker 1: And what about the topical versus systemic debate? How does
- 8:10Speaker 1: this play out in practice?
- 8:11Speaker 2: That's a valid concern. Topical administration is more convenient, but
- 8:16Speaker 2: systemic delivery might offer broader benefits. The goal is to
- 8:20Speaker 2: find the best balance between ease of use and overall effectiveness.
- 8:24Speaker 2: Ongoing studies will help us understand which approach works best
- 8:27Speaker 2: for different scenarios.
- 8:28Speaker 1: Well, we are certainly looking forward to seeing how these
- 8:31Speaker 1: studies pan out. Palm LBH dust potential is undoubtedly exciting,
- 8:37Speaker 1: but we have got a long way to go before
- 8:39Speaker 1: we know for sure.
- 8:40Speaker 2: Exactly. But the journey is as important as the destination,
- 8:44Speaker 2: and every step brings us closer to new, potentially life-changing treatments.
- 8:49Speaker 1: So, let's dig into the critical debates surrounding Palm LBH dew.
- 8:54Speaker 1: We have seen the promising preclinical data, but moving to
- 8:58Speaker 1: human studies introduces a whole new set of challenges. How
- 9:04Speaker 1: do we reconcile efficacy with safety in these initial trials?
- 9:07Speaker 2: Right, and that's the crucial nuance here. Preclinical data looks great,
- 9:12Speaker 2: but translating those results to a clinical setting is tricky.
- 9:16Speaker 2: One of the key debates is about the extrapolation of
- 9:18Speaker 2: these findings. For instance, the topical application showing strong antiviral
- 9:24Speaker 2: activity in mice might not translate directly to human skin responses.
- 9:28Speaker 2: We need to be cautious of those leaps and really
- 9:31Speaker 2: focus on human safety first.
- 9:33Speaker 1: Exactly. which brings up an interesting contradiction. The multi-target specificity
- 9:38Speaker 1: of POM-LBH2 seems like a game-chainer, but it's also a
- 9:42Speaker 1: double-edged sword. This broad spectrum of activity means to raise
- 9:47Speaker 1: less certainty in how it will perform specifically against each virus. Right?
- 9:51Speaker 2: Precisely. And this uncertainty is compounded when you consider the
- 9:55Speaker 2: variations in viral populations. For example, there are different strains
- 10:00Speaker 2: of the herpes simplex virus, and their responses to antivirals
- 10:04Speaker 2: can vary greatly. Clinical trials need to account for these
- 10:08Speaker 2: nuances and provide robust data on how the drug behaves
- 10:11Speaker 2: under different conditions.
- 10:13Speaker 1: Speaking of which, comparing POM-LBH2 with existing treatments is another
- 10:18Speaker 1: big aspect. Antiviral drugs like acyclovir have been around for decades.
- 10:25Speaker 1: How does POM-LBH2 stack up?
- 10:27Speaker 2: Great point. Right now, the comparison is mostly theoretical. POM-LBH2's
- 10:33Speaker 2: multi-target approach could offer unique benefits, especially in mixed infections
- 10:38Speaker 2: or where resistance to other treatments is a concern. But
- 10:41Speaker 2: these advantages need to be tested and validated through rigorous
- 10:44Speaker 2: clinical trials. And let's not forget, established drugs like acyclovir
- 10:49Speaker 2: have a proven track record and clinical guidelines, making them
- 10:53Speaker 2: the current go-to for many clinicians.
- 10:56Speaker 1: Exactly. These guidelines are already deeply rooted in healthcare routines.
- 11:01Speaker 1: Introducing a new drug into this landscape means navigating the
- 11:05Speaker 1: resistance of both practitioners and patients. But beyond the clinical aspect,
- 11:10Speaker 1: we also need to weigh the convenience and safety of POM-LBH2.
- 11:15Speaker 1: against other treatment methods.
- 11:16Speaker 2: That's true. The system of oral versus topical application, for instance,
- 11:22Speaker 2: introduces another layer of complexity. Oral administration ensures systemic delivery,
- 11:28Speaker 2: which could offer broader benefits. However, topical formulations might be
- 11:33Speaker 2: more practical for localized infections. Balancing these factors in clinical
- 11:38Speaker 2: trials is key to ensuring we make the most of
- 11:41Speaker 2: POM-LB2 potential.
- 11:43Speaker 1: Agreed. And what about the long-term use and repeated dosing?
- 11:48Speaker 1: Will POM-LBH2 prove just as effective over extended periods? Or
- 11:53Speaker 1: will its efficacy wane? These are critical questions that need
- 11:58Speaker 1: to be answered. Absolutely.
- 12:00Speaker 2: That's one of the biggest unknowns. Long-term studies will help
- 12:04Speaker 2: us understand the drug's persistence and potential side effects. Right now,
- 12:08Speaker 2: our focus is on the immediate safety and efficacy. But
- 12:12Speaker 2: the real test will come with sustained use, and we
- 12:15Speaker 2: need to be prepared for the possibility that what works
- 12:18Speaker 2: in the short term might not hold up in the
- 12:20Speaker 2: long term.
- 12:20Speaker 1: Well, that's a lot to unpack, Thomas. As we close
- 12:24Speaker 1: this section, it's clear that the journey from preclinical data
- 12:28Speaker 1: to actual implementation is fraught with challenges, but the potential
- 12:32Speaker 1: benefits are equally compelling. Let's stay tuned for future updates
- 12:37Speaker 1: and clinical trial results.
- 12:38Speaker 2: Indeed, let's keep the pressure on for the trials and
- 12:41Speaker 2: hold them accountable. After all, the end goal is finding
- 12:45Speaker 2: the best and safest treatment for those suffering from these infections.
- 12:49Speaker 1: With all the exciting advancements and the potential impact POM
- 12:52Speaker 1: LBH2 could have, it's clear that the road ahead is
- 12:56Speaker 1: paved with both promise and challenges. Let's dive into the
- 13:00Speaker 1: upcoming clinical trials and what we can expect from these investigations.
- 13:04Speaker 2: Absolutely, Rachel. The upcoming trials are pivotal. They will not
- 13:08Speaker 2: only test the efficacy of the drug but also its
- 13:11Speaker 2: safety and long-term effects. For instance, the phase I trials
- 13:16Speaker 2: are about to assess the drug's initial safety profile in
- 13:19Speaker 2: a small group of human participants.
- 13:21Speaker 1: Right. And that's the crucial nuance here. We need to
- 13:24Speaker 1: ensure the drug isn't just effective, but also safe for
- 13:28Speaker 1: human use, especially considering the complexities of these viral infections.
- 13:33Speaker 2: Precisely. Moving on, the Phase II trials will expand the
- 13:37Speaker 2: study to a larger group of people to evaluate how
- 13:40Speaker 2: the drug performs under different circumstances. This is where we
- 13:44Speaker 2: will see if POM-LBTU can deliver consistent results and if
- 13:48Speaker 2: there are any side effects that weren't evident in the
- 13:51Speaker 2: smaller sample.
- 13:52Speaker 1: And then the Phase III trials, bigger and better, with
- 13:56Speaker 1: the goal of confirming the drug's efficacy and side effects
- 13:59Speaker 1: in a diverse population. This is where we will get
- 14:03Speaker 1: that all-important real-world data to make informed decisions about potential
- 14:09Speaker 1: approval and implementation.
- 14:11Speaker 2: Exactly, which brings up an interesting contradiction. While these trials
- 14:16Speaker 2: are key, they also introduce a level of uncertainty. The
- 14:20Speaker 2: results won't just reflect the drug's performance, but also the
- 14:23Speaker 2: specific population and conditions under which the tests are conducted.
- 14:27Speaker 1: That's wild when you look at the raw numbers. For
- 14:30Speaker 1: example … Different demographics might react differently to the drug,
- 14:34Speaker 1: and we need to account for variables like age, sex,
- 14:38Speaker 1: and underlying health conditions.
- 14:39Speaker 2: Yes, exactly. The trial outcomes will be crucial in determining
- 14:43Speaker 2: the drug's impact on antiviral therapy. Positive results could revolutionize
- 14:48Speaker 2: how we handle cases of shingles, chickenpox, and herpes, providing
- 14:52Speaker 2: a safer, more effective, and perhaps more convenient treatment option. Right.
- 14:57Speaker 1: And this is where the potential for POM-LBH2 shines. If
- 15:01Speaker 1: the trials are successful, it could open up a new
- 15:04Speaker 1: chapter in antiviral therapeutics.
- 15:07Speaker 2: Absolutely. But let's not get ahead of ourselves. The future
- 15:11Speaker 2: outlook depends on how these trials pan out. Negative results
- 15:15Speaker 2: could still provide valuable insights, refining our understanding of how
- 15:19Speaker 2: these viruses work and how we can target them more effectively.
- 15:22Speaker 1: Exactly. The journey from promising lab results to actual patient
- 15:26Speaker 1: treatment is complex, and the clinical trials are just the
- 15:29Speaker 1: beginning of a long and rigorous process. But the ultimate
- 15:33Speaker 1: goal is clear, to improve patient outcomes and the quality
- 15:36Speaker 1: of life for those suffering from these infections. So, Thomas,
- 15:40Speaker 1: as we look ahead, what strategic implications do you think
- 15:43Speaker 1: the current status of POM-LBH2 and future clinical trials could
- 15:47Speaker 1: have on antiviral drug development in general?
- 15:49Speaker 2: Well, Rachel, the implications are profound. If POM-LBH2 proves to
- 15:54Speaker 2: be as effective as early trials suggest, it will likely
- 15:58Speaker 2: catalyze innovation in antiviral drug design. emphasizing the importance of
- 16:03Speaker 2: broad-spectrum antiviral therapy. This could drive research towards developing more
- 16:08Speaker 2: versatile compounds that can target multiple viruses efficiently.
- 16:13Speaker 1: Exactly. And it doesn't stop there. The multi-target approach might
- 16:17Speaker 1: open new pathways for treating viral infections that are currently
- 16:20Speaker 1: difficult to manage or have limited treatment options. For example,
- 16:24Speaker 1: what do you see as the impact on vaccine research
- 16:27Speaker 1: and development for these viruses?
- 16:28Speaker 2: It could completely reshape our approach. We might see a
- 16:32Speaker 2: shift towards more complex, multi-component vaccines that could protect against
- 16:36Speaker 2: a variety of related viruses. This would be a big
- 16:40Speaker 2: leap from the current single-target vaccine approach. Plus, the success
- 16:44Speaker 2: or failure of POM-LB2 in human trials could inform vaccine
- 16:49Speaker 2: design principles, emphasizing the necessity for broader immune modulation strategies.
- 16:54Speaker 1: And what about the broader economic implications if this drug
- 16:58Speaker 1: does revolutionize treatment methods? could it significantly alter drug pricing
- 17:04Speaker 1: and distribution models?
- 17:05Speaker 2: Potentially, yes. If palm oil Bidu becomes widely adopted, it
- 17:10Speaker 2: could challenge the current pharmaceutical landscape by forcing companies to
- 17:14Speaker 2: reconsider their pricing and distribution strategies. We might see a
- 17:18Speaker 2: push towards more affordable treatment options if a multifunctional compound emerges,
- 17:23Speaker 2: given the potential to reduce overall healthcare costs.
- 17:26Speaker 1: True. But let's not forget the policy implications. How could
- 17:31Speaker 1: advancements in antiviral therapy shape public health policies and strategies?
- 17:36Speaker 2: Public health policies could shift to include more comprehensive approaches
- 17:39Speaker 2: to viral disease management. This might involve not just treatment,
- 17:43Speaker 2: but also prevention strategies, with stronger emphasis on early detection
- 17:48Speaker 2: and intervention. The success of POMEL Beach Dew could also
- 17:51Speaker 2: lead to better resource allocation in virus research and development,
- 17:56Speaker 2: ensuring more funding for emerging threats.
- 17:58Speaker 1: Exactly. And on a practical level, what do you think
- 18:02Speaker 1: healthcare providers and patients can expect in the coming years
- 18:06Speaker 1: as a result of advancements like POM-LBH do?
- 18:10Speaker 2: Healthcare providers might see a broader range of treatment options,
- 18:14Speaker 2: making it easier to address viral infections with fewer side effects.
- 18:18Speaker 2: For patients, this could mean more effective, targeted therapies and
- 18:22Speaker 2: potentially fewer hospitalizations. It's a real possibility that we could
- 18:26Speaker 2: see a reduction in the burden of viral infections on
- 18:29Speaker 2: both the healthcare system and individual patients.
- 18:33Speaker 1: Right. The future of antiviral drug development looks promising, with
- 18:37Speaker 1: POM-LBH2 serving as a catalyst. But as we move forward,
- 18:43Speaker 1: it's important to continue rigorous, critical evaluation of these compounds
- 18:47Speaker 1: to ensure they live up to their early promise.
- 18:50Speaker 2: Agreed. The coming years will be crucial for Pomel Bidu
- 18:54Speaker 2: and other potential antiviral therapies. But the broader lesson is clear.
- 18:59Speaker 2: We need ongoing investment in research and development to combat
- 19:02Speaker 2: the ever-evolving landscape of viral diseases.
- 19:05Speaker 1: That brings us to the end of today's episode. Thank
- 19:08Speaker 1: you so much for spending part of your day with me.
- 19:10Speaker 1: If you found this episode's tips helpful and want to
- 19:12Speaker 1: make sure you don't miss the next conversation, please take
- 19:16Speaker 1: a quick second to hit that subscribe or follow button
- 19:19Speaker 1: on whatever platform you are listening on. It's a completely
- 19:22Speaker 1: free way to support the show and helps more people
- 19:24Speaker 1: find us. This podcast is independently produced, so if you
- 19:28Speaker 1: are ever in a position where you would like to
- 19:30Speaker 1: help keep it running, we do accept small donations. You
- 19:34Speaker 1: can find a link right in the episode description below
- 19:36Speaker 1: to buy us a coffee or contribute what you can.
- 19:39Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 19:44Speaker 1: and we will talk again soon.